The Investment Column: Key trials on track for British Biotech
Wednesday 26 November 1997
In a massive study, marimastat is being tested on six different tumour types, in combination with cytotoxics and eventually on early stage cancers. Familiarising doctors with marimastat ahead of its registration and demonstrating its potential in as many cancers as possible could make this a billion- dollar seller. Doctors frequently prescribe trusted cancer drugs more broadly than their indicated use.
As well as building up a sales force in Europe and eventually in the US, British Bio plans to buy in "accessories" such as like anti-nausea and anti-pain drugs to provide oncologists with a full cancer kit. With marimastat at least 18 months away from filing, such massive up-front investment raises the stakes.
True, British Bio has plenty of cash and a lead drug, Zacutex for pancreatitis, which could be filed in Europe in early 1998, but if marimastat fails British Bio will struggle to recover. But serious drugs require serious backing. Glaxo's Zantac became a blockbuster not because it was a such a great ulcer remedy, but because every doctor knew about it. British Biotech's shares down 2.5p to 103p, near their year low, are a buy for those who understand the risks.
- 1 Video of Irish 'professional boxer' fighting Istanbul neighbourhood goes viral in Turkey
- 3 Toby Sheldon: Justin Bieber lookalike found dead in motel room
- 4 Russia 'accidentally reveals' number of its soldiers killed in eastern Ukraine
- 5 Pregnant teenager Neysi Perez 'wakes up in coffin' a day after her funeral
Video of Irish 'professional boxer' fighting Istanbul neighbourhood goes viral in Turkey
Nazi gold train: 'Significant' discovery made in Poland
Toby Sheldon: Justin Bieber lookalike found dead in motel room
Horses 'neglected for 15 years' found with 3ft-long hooves
Russia 'accidentally reveals' number of its soldiers killed in eastern Ukraine
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith calls for urgent ESA overhaul as part of drive to cut down welfare costs
iJobs Money & Business
£20000 - £25000 per annum + competitive: SThree: Are you passionate about sale...
£25000 per annum + benefits: Ashdown Group: A large financial services company...
£20400 per annum: Ashdown Group: An established and highly reputable organisat...
£20000 - £100000 per annum: Recruitment Genius: We are a successful and establ...